Knight Therapeutics (TSX:GUD) Net Income (Continuing Operations): C$14.9 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:GUD Knight Therapeutics Inc TSX:GUD
73 GF Score
Price C$10.25
GF Value C$9.24
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Knight Therapeutics Net Income (Continuing Operations)?

Knight Therapeutics TSX:GUD +0.20% 73 Net Income (Continuing Operations) is C$14.9 Mil as of Jun. 2026. GuruFocus rates TSX:GUD with a GF Score™ of 73/100 and a GF Value™ of C$9.24 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Knight Therapeutics's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was C$-3.4 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was C$14.9 Mil.

Knight Therapeutics  (TSX:GUD) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Knight Therapeutics Net Income (Continuing Operations) Related Terms

Knight Therapeutics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics Net Income (Continuing Operations) Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.68 -29.89 -16.84 4.33 -5.37

Knight Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.62 -3.79 8.85 13.17 -3.36
TSX:GUD
73GF Score
Knight Therapeutics Inc TSX:GUD
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$14.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of C$14.9 Mil mean?
Knight Therapeutics (TSX:GUD) has a Net Income (Continuing Operations) of C$14.9 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Knight Therapeutics and its competitors.
Is Knight Therapeutics' Net Income (Continuing Operations) too high?
Knight Therapeutics' current Net Income (Continuing Operations) is C$14.9 Mil. Overall, Knight Therapeutics has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' Net Income (Continuing Operations) compare to ZTS?
Knight Therapeutics' Net Income (Continuing Operations) of C$14.9 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Knight Therapeutics and its competitors. Knight Therapeutics's current Net Income (Continuing Operations) is C$14.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Knight Therapeutics (TSX:GUD) is currently considered Modestly Overvalued. The stock's GF Value™ is C$9.24, compared to a current price of C$10.25 — trading 10.9% above its estimated fair value. The current Net Income (Continuing Operations) is C$14.9 Mil. Knight Therapeutics' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Knight Therapeutics (TSX:GUD), the current Net Income (Continuing Operations) is C$14.9 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (TSX:GUD) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of C$10.25 is trading 10.9% above its estimated GF Value™ of C$9.24. GuruFocus considers Knight Therapeutics to be Modestly Overvalued.

Key valuation signals for TSX:GUD:

  • Net Income (Continuing Operations): C$14.9 Mil
  • GF Value™: C$9.24 vs. price of C$10.25 (10.9% above fair value)
  • GF Score™: 73/100 with 3 warning signs

No single metric tells the full story. See the TSX:GUD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Knight Therapeutics Business Description

Other Exchanges KHTRF:USA
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for TSX:GUD

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$10.25
Price
C$9.24
GF Value